| 1301212-64-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• CAS: 1301212-64-5
• 化学式: C₂₈H₄₃NO₅
• 分子量: 473.653
• InChiKey: ORUBGMJEBMAMOA-QWAXUUMUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.34
• 重原子数：
  34.0
• 可旋转键数：
  9.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  82.03
• 氢给体数：
  0.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  、 3-苯基丙-2-烯-1-醇 以 甲苯 为溶剂， 生成 23-N-(carbocinnamyloxy)-3α,7α-diformyloxy-6α-ethyl-24-nor-5β-cholan-23-amine
  参考文献：
  名称：

  Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine

  摘要：

  Within our efforts in the discovery of novel potent and selective ligands for the FXR receptor, 23-N-(carbocinnamyloxy)-3 alpha,7 alpha-dihydroxy-6 alpha-ethyl-24-nor-5 beta-cholan-23-amine was synthesized and evaluated for its ability to activate and modulate the biological response of the receptor. Alphascreen and RT-PCR revealed that the 6 alpha-ethyl-24-norcholanyl-23-amine derivate behaves as full FXR agonist endowed with high binding affinity and efficacy, representing a promising lead candidate for further optimization. In addition, docking studies provide new insights into the molecular basis governing the partial and full agonist activity at FXR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.004
• 作为产物：
  描述：

  methyl 3α-hydroxy-6-ethylidene-7-keto-5β-cholanate 在 盐酸 、 platinum(IV) oxide 、 sodium tetrahydroborate 、 sodium azide 、 草酰氯 、 水 、 氢气 、 对甲苯磺酸 、 溶剂黄146 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 、 丙酮 、 甲苯 、 苯 为溶剂， 45.0 ℃ 、220.64 kPa 条件下， 反应 36.0h， 生成
  参考文献：
  名称：

  Extending SAR of bile acids as FXR ligands: Discovery of 23-N-(carbocinnamyloxy)-3α,7α-dihydroxy-6α-ethyl-24-nor-5β-cholan-23-amine

  摘要：

  Within our efforts in the discovery of novel potent and selective ligands for the FXR receptor, 23-N-(carbocinnamyloxy)-3 alpha,7 alpha-dihydroxy-6 alpha-ethyl-24-nor-5 beta-cholan-23-amine was synthesized and evaluated for its ability to activate and modulate the biological response of the receptor. Alphascreen and RT-PCR revealed that the 6 alpha-ethyl-24-norcholanyl-23-amine derivate behaves as full FXR agonist endowed with high binding affinity and efficacy, representing a promising lead candidate for further optimization. In addition, docking studies provide new insights into the molecular basis governing the partial and full agonist activity at FXR. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.03.004